Company Profile

Renovacor, Inc. is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The Company's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The Company is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company's preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

22-12-01	Renovacor, Inc.(NYSEAM:RCOR) dropped from S&P TMI Index	CI
22-11-30	Rocket Pharmaceuticals, Inc. completed the acquisition of Renovacor, Inc. from RTW Investments, LP, Chardan Investments 2, LLC and others,	CI
22-11-10	Renovacor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-09-21	Baird Downgrades Renovacor to Neutral From Outperform, Adjusts Price Target to $2.75 From $9	MT
22-09-21	BTIG Downgrades Renovacor to Neutral From Buy	MT
22-09-20	Ladenburg Thalmann Downgrades Renovacor to Neutral From Buy, Adjusts Price Target to $2.60 From $22	MT
22-09-20	Wall Street Set to Open Lower Ahead of Fed Meeting	MT
22-09-20	US Futures Lower as Investors Gird for Another Fed Rate Increase	MT
22-09-20	Renovacor, Inc., Rocket Pharmaceuticals, Inc. - M&A Call
22-09-20	Top Premarket Gainers	MT
22-09-20	Rocket Pharmaceuticals to Acquire Renovacor in $53 Million All-Stock Deal	MT
22-09-19	Rocket Pharmaceuticals, Inc. entered into a definitive agreement to acquire Renovacor, Inc. from RTW Investments, LP, Chardan Investments 2, LLC and others for $49.1 million.	CI
22-09-14	BTIG Starts Renovacor at Buy With $8 Price Target	MT

22-09-21	Baird Downgrades Renovacor to Neutral From Outperform, Adjusts Price Target to $2.75 From $9	MT
22-09-21	BTIG Downgrades Renovacor to Neutral From Buy	MT
22-09-20	Ladenburg Thalmann Downgrades Renovacor to Neutral From Buy, Adjusts Price Target to $2.60 From $22	MT
22-09-14	BTIG Starts Renovacor at Buy With $8 Price Target	MT
22-09-13	Baird Initiates Renovacor at Outperform With $9 Price Target	MT

22-11-10	RENOVACOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
22-10-14	RENOVACOR, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
22-10-11	Renovacor Announces Upcoming Presentation at the 29th European Society of Gene and Cell Therapy Congress	AQ
22-10-10	Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress	BU
22-09-27	Renovacor Announces Upcoming Presentation at Keystone Symposia's Heart Failure, Mechanisms and Therapies Conference	AQ

Manager	Title	Age	Since
Jordan Shin CTO	Chief Tech/Sci/R&D Officer	-	-
Elizabeth White COO	Chief Operating Officer	-	-
Kumar Dhanasekharan CTO	Chief Tech/Sci/R&D Officer	-	2021-10-03

Director	Title	Age	Since
Gbola Amusa BRD	Director/Board Member	52	2021-09-01
Edward Benz BRD	Director/Board Member	80	2017-06-30
Gregory Covino BRD	Director/Board Member	61	2021-09-01

Renovacor, Inc. Stock

Stocks

RCOR

US75989E1064

Biotechnology & Medical Research

Latest news: Renovacor, Inc.

Analysts' recommendations: Renovacor, Inc.

Press Releases: Renovacor, Inc.

Quotes and Performance

Managers and Directors: Renovacor, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/1/22	Joseph Carroll	Issuer sale	Controller/Auditor	79,429	0.4599%
12/1/22	Jonas Grossman	Issuer sale	Director	430,657	2.4938%
12/1/22	Gbola Amusa	Issuer sale	Director	314,588	1.8216%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RENOVACOR, INC.	+4.92%	+7.93%	-	-	53.66M
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.38B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	56.16B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	54.16B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.33B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.25B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.78B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	33.8B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.64%	-3.32%	+21.05%	-12.32%	23.57B
Average	+0.28%	+4.50%	+52.21%	+162.51%	43.63B
Weighted average by Cap.	+0.00%	+3.60%	+49.15%	+161.38%